Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant-Reference-Cited by-同舟云学术

Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant

Published:2021-08-19 Issue:9 Volume:18 Page:3509-3518
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Zhang Zhe¹,Wang Xiaobo¹^ORCID,Ye Jiajun²,Liu Huanhuan¹,Fang Jianyang¹,Zhang Mingru²^ORCID,Li Yesen³,Huang Jinxiong³,Zhang Deliang¹,Wang Jing²^ORCID,Zhang Xianzhong¹^ORCID

Affiliation:

1. Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China

2. Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China

3. Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China

Funder

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.1c00426

Reference37 articles.

1. RAS oncogenes: weaving a tumorigenic web